Results from the Phase 3 ECLIPSE trial, comparing guselkumab and secukinumab for the treatment of moderate-to-severe psoriasis, were published on 2019-01-01. This pivotal randomized controlled trial evaluated the comparative efficacy of the two drugs in patients with plaque-type psoriasis.
Background
The ECLIPSE trial focused on the treatment of moderate-to-severe plaque-type psoriasis, a chronic inflammatory skin condition. Secukinumab (Cosentyx) was evaluated against guselkumab in this patient population.
Trial design
The Phase 3 ECLIPSE trial was a randomized controlled study designed to evaluate the comparative efficacy of guselkumab and secukinumab. The study enrolled participants with moderate-to-severe plaque-type psoriasis, aiming to assess which treatment demonstrated superior or comparable outcomes for this condition.
What this means
The publication of the Phase 3 ECLIPSE trial results provides clinicians and researchers with data on the comparative efficacy of guselkumab and secukinumab for moderate-to-severe plaque-type psoriasis. While specific outcome measurements are not detailed in the provided information, the trial's focus on head-to-head comparison is significant for treatment decisions. Understanding the relative benefits of these two treatments can help guide therapeutic strategies for patients with this chronic skin condition.
Source
The results of the ECLIPSE trial were published on 2019-01-01. The information was sourced from PubMed, specifically from a publication titled 'Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. (Lancet)' available on pubmed.ncbi.nlm.nih.gov.